Home » Inyx to Produce Non-Ozone-Depleting Asthma Inhaler for Merck
Inyx to Produce Non-Ozone-Depleting Asthma Inhaler for Merck
April 21, 2005
Inyx, a specialty pharmaceutical company with a focus on niche drug delivery technologies and products, announced that its wholly owned subsidiary Inyx Pharma Limited has been selected by Generics (UK) Ltd, a unit of Merck Generics Group, a global pharmaceutical company, to produce for worldwide markets a non-ozone-depleting hydrofluoroalkane (HFA) salbutamol inhaler for the treatment of asthma and other chronic respiratory conditions. The initial contract is for four years with automatic renewal options, and production is scheduled to commence before the end of 2005 at Inyx Pharma's manufacturing center in the United Kingdom.
Yahoo News (http://biz.yahoo.com/prnews/050421/neth011.html?.v=9)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct